13th Euro Abstracts six assessments that resulted in conditional reimbursement were targeted therapies. Typically, with these targeted therapies, PFS or OS ranged from ~3 months to 9 months with the cost-per-QALY > £45.000. Five of the six manufactures participated in a patient-access scheme which consisted of fi xed-price discounts such as Cetuximab (CRC) and Gefi tinib (NSCLC) or performance schemes like sunitinib (GIST), Bortezomib (myeloma), and Lenalidome (myeloma). CONCLUSIONS: Based on the retrospective analysis, it is clear that the biggest challenge for targeted-cancer therapies is affordability with only one of the targeted therapies receiving unconditional reimbursement. However, nearly all the other targeted therapies evaluated that offered >3 months OS or PFS were recommended by NICE with a proviso to bring down the cost of treatment. Therefore, when companies develop their market access strategy, they should include a patient-access scheme in order to enter the UK market.
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NI2 PATIENT ACCESS SCHEMES IN UK ARE DRIVEN BY HEALTH TECHNOLOGY ASSESMENT
Toumi M 1 , Jaroslawski S 2 1 University of Lyon, Lyon, France; 2 Creativ Ceutical, Paris, Ile de France, France OBJECTIVES: Achieving market access for new products has become complex for pharmaceutical companies. Faced with growing expenditure, health-care authorities accept or propose various schemes (risk sharing/payment for performance/commercial): UK's Department of Health coined a term Patient Access Scheme (PAS) and published specifi c guidance for the industry. We performed an in-depth analysis of design of PASs in UK to revisit their typology and rationale. METHODS: We reviewed offi cial and grey literature on the Web sites of UK's HTA Agency-NICE, the Department of Health (DoH), the industry, and in the Internet. We searched for documents containing all synonimes of PAS and different scheme types. We selected PASs launched after 2006. RESULTS: We identifi ed 13 PASs, all of which were designed/ implemented in consultation with NICE. Drug's comparative effectiveness was central to the rationale behind the design of PASs. If effectiveness was acknowledged in the HTA, PAS was based on cost-containment (rituximab, erlotinib). If it was not recognized, this was for one of the two reasons: (1) the uncertainity about the long-term effect of the drug, or (2) the value of ICER was questioned in the HTA. In case of (1), the PAS consisted in free provision of the drug by manufacturer after a predefi ned period (lenalidomide, ranibizumab). In the case of (2), the PAS aimed at lowering the ICER either through cost containment (sunitinib, cetuximab, pemetrexed), through linking payment to outcomes (bortezomib, omalizumab), or by a mix of the two (certolizumab, ustekinumab) . CONCLUSIONS: Formalized Health Technology Assessment is both a prerequisite and reason for implementing Patient Access Schemes in the UK. If the comparative effectiveness of a drug is acknowledged, the agreement is based on cost containment. On the other hand, if it is questioned, the PAS may have a form of a risk-sharing scheme and may be linking the payment to health outcomes (performance-based scheme). Since its establishment, NICE has become increasingly explicit about the way it uses evidence on cost-effectiveness in decision-making-and, more recently, about the other factors it considers. This, together with other ways in which decisionmaking has evolved, suggests a number of testable hypotheses. We propose and empirically test alternative ways that NICE decision-making might be modeled, building on and extending Devlin and Parkin (2004) and Dakin et al. (2006) . The large number of NICE decisions now observable facilitates the use of more sophisticated modeling techniques. METHODS: NICE's decisions are characterized as binary choices: yes or no to a technology in a specifi cally defi ned patient group or indication. NICE Guidance often contains multiple such decisions. The probability of NICE recommending a technology is modeled as depending on evidence on effectiveness and cost-effectiveness; characteristics of the patients, disease, or treatment; and contextual factors. Data were obtained from HTAinSite (http://www.htainsite.com) on November 2009. RESULTS: Initial results, drawing on data for 262 decisions, suggest costeffectiveness alone explains the vast majority of NICE's decisions, correctly classifying 85%, with high sensitivity and specifi city. The estimated threshold, around £40k, is higher than NICE's stated threshold (20k-£30k) but similar to that estimated by Devlin and Parkin (2004) . Results across alternative model specifi cations showed that almost none of the other variables exert a statistically signifi cant effect on decisions, with two exceptions. First, technologies for the treatment of cancer have a signifi cantly higher probability of being accepted, ceteris paribus, implying a willingness to pay an additional >£10k per QALY gained by cancer patients. Second, analysis of the subset of decisions made after NICE's second "social value judgement" document suggest an increased probability of rejection. CONCLUSIONS: This is work in progress; further results will be available to report from additional data extraction and modeling.
NI3 NICE'S COST-EFFECTIVENESS THRESHOLD REVISITED: NEW EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS

NI4 DO PATIENT ACCESS SCHEMES RESULT IN AN ACCEPTABLE ADMINISTRATIVE BURDEN?
Haynes S, Costello S, Kusel J, Hamer N, Brooks-Rooney C Costello Medical Consulting Ltd., Cambridge, UK OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become more common in submissions to the National Institute for Health and Clinical Excellence (NICE). The increase in PAS is a result of the essential role such schemes play in enhancing the availability of high-cost treatments to payers. In published appraisals, minimal emphasis has been placed upon the administrative burden of PAS, which is typically described as "acceptable." The aim of this study was to assess the impact of administering PAS in the UK, using both primary research and existing literature to identify key administrative challenges. METHODS: A literature search was conducted using PubMed and Google Scholar. Freedom of information requests were sent to NICE for data on PAS administration. a pilot questionnaire was distributed to all 19 contacts listed on the directory of NHS Chief Pharmacists in Wales, to assess the real-life burden of PAS administration. RESULTS: Limited literature is available on the administration of PAS. However, the literature search uncovered evidence that the administrative impact of PAS is being recognized. The creation of the Patient Access Scheme Liaison Unit (PASLU) in October 2009 and the publication of the Pharmaceutical Price Regulation Scheme (PPRS) are two such developments, both of which are steps toward a system that more accurately refl ects the needs of NHS administrators. The return rate for the questionnaire was low; however, responders showed dissatisfaction with multiple aspects of PAS management. Responders emphasized the need to address NHS requirements (both fi nancial and temporal) in order to facilitate accurate PAS administration. CONCLUSIONS: Encouraging steps have been taken to recognize the burden of PAS on the NHS; however, further research is required to assess whether these recent developments are meaningful in everyday practice. Additional support for appropriate PAS implementation must also be provided if these important schemes are to continue effectively. Offering patients in oncology trials the opportunity to cross over to active treatment at disease progression is a commonly used strategy to address ethical issues associated with the use of placebo controls, but could lead to statistical challenges for the analysis of key end points such as overall survival. While an advantage from the perspective of the treated patient enrolled in the trial, cross-over leads to loss of information and dilution of the comparative clinical effi cacy and costeffectiveness results. OBJECTIVES: The purpose of the study is to compare alternative methods for analyzing overall survival data in the presence of cross-over, thus illustrating differences between methods, and providing guidance on choice of methodology. METHODS: Two promising methods for dealing with cross-over are inverse probability of censoring weighting and the rank-preserving structural failure time model. The methods are compared with naïve censoring of data at cross-over and intention-totreat analysis ignoring cross-over using two recent examples of trials in oncology: the receptor tyrosine kinase inhibitor sunitinib in renal cell carcinoma (RCC) and in gastrointestinal stromal tumor (GIST). RESULTS: The analyses showed that for a trial with a low proportion of cross-over from placebo to active treatment (RCC), the choice of statistical method did not affect the results to a great extent; the range of relative mortality risk for active treatment versus control was narrow. With a high proportion of cross-over (GIST), the range of relative mortality risks was broader. CONCLUSIONS: Naïve censoring at cross-over can lead to bias and should be avoided. If cross-over occurs frequently, the inverse probability of censoring weighting method or the rank-preserving structural failure time model are recommended depending on the characteristics of cross over in the trial, trial size, and available data.
PODIUM SESSION III: BIASES, METHODOLOGICAL CHALLENGES, AND SOLUTIONS
BI1 ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS WITH CROSS-OVER
BI2 MULTIPLE COHORT MODELING OF LONG-DURATION INTERVENTIONS: QUESTIONING TIME HORIZONS AND AGGREGATION ACROSS COHORTS
O'Mahony J Erasmus University Medical Center, Rotterdam, The Netherlands BACKGROUND: Models are widely used in the cost-effectiveness analysis of healthcare interventions. Most models only simulate one patient cohort, but some use multiple cohorts. Advocates of multicohort modeling contend it better represents actual health-care implementation, especially where interventions are applied over specifi c age ranges, as in cancer screening. When such an intervention is introduced, cohorts already older than the starting age only receive a partial intervention, possibly 13th Euro Abstracts A247 resulting in cost-effectiveness different to that of younger cohorts that receive the complete intervention: multi-cohort models can include both these "complete" and "partial" cohorts. Some multi-cohort models described as population models impose fi nite time horizons at which the intervention is assumed to cease, although health effects are typically assessed until death. ANALYSIS: If cost-effectiveness differs between partial and complete cohorts, then the overall cost-effectiveness estimate from a multi-cohort model will depend on the relative numbers of partial and complete cohorts. The total number of complete cohorts depends on how long the intervention is used, which is uncertain. Therefore, the overall estimate may depend, in part, on the number of future cohorts assumed. The appropriateness of time horizons depends on whether a cross-sectional or a longitudinal cohort approach is used. Assuming an intervention ceases at a time horizon is unrepresentative of actual implementation and may result in biased cost-effectiveness estimates for curtailed cohorts. CONCLUSION: Multi-cohort modeling is advocated as being more representative of actual implementation. However, a single cost-effectiveness estimate for multiple cohorts necessarily implies an aggregation of estimates. Such aggregation leaves estimates sensitive to assumptions of the number of cohorts included, can hide useful information, and lead to nonoptimal policy choices. We suggest cost-effectiveness estimates for the complete and incomplete cohorts should not be aggregated, but reported separately. Implementation time horizons should not be used in longitudinal cohort-based modeling in cost-effectiveness analysis.
BI3 COMMON AND AVOIDABLE ERRORS IN ECONOMIC MODELING: A REVIEW OF THE FREQUENCY AND IMPACT OF MODELING MISTAKES
Taylor M, Kenworthy J, Lewis L York Health Economics Consortium, York, North Yorkshire, UK BACKGROUND: Cost-effectiveness models are often used to predict the costs and health outcomes that are likely to be associated with various different interventions. Models are a useful tool for representing the detailed and complex "real world" in a more simple and understandable structure. While models do not claim to necessarily create an exact replica of the real world, they can be useful in demonstrating the relationships and interactions between various different factors. However, developers of models often consciously, and unconsciously, make assumptions that are avoidable and may bias the results of a model. METHODS: A review was undertaken on a random selection of published models in different disease areas to aim to identify the frequency of typical "errors" in economic models. In addition, a simple model was developed and used to explore the relative impact of different types of errors in models. Each type of error was examined for its likely impact on the model's overall fi ndings and conclusions. This helped to gain a greater understanding of both the frequency of different errors and their magnitude of effect. RESULTS: Mistakes are commonly observed in economic models. These were often due to limitations in scope of the model, but all were found to be avoidable given unlimited time and data availability. As well as identifying "major" errors in models, the review also identifi ed many common errors, such as excluding "half cycle correction," that often have very little impact on a model's results, relative to other common errors. CONCLUSIONS: While many errors in economic models are frequent, many errors often go unnoticed and have signifi cant impact upon a model's results. This analysis has highlighted the relative importance of each type of error and has provided suggestions as to how these might be avoided. Discrepancies in diagnosis, treatment, or prognosis may emerge among physicians. a known decision-making bias is the tendency to shift personal opinion either toward or away from a previous opinion. We sought to evaluate such biases in the context of second-opinion medical consultations. METHODS: We distributed a survey questionnaire to a nationwide sample of orthopedic surgeons and neurologists. The questionnaires presented eight scenarios, each with conventional treatment options with no clear-cut preference. In four scenarios, the physicians were told that a previous opinion had already been given by another physician, or that a second opinion will be given, and the other four scenarios were used as controls. The physicians' responses were coded according to the level of intervention (conservative to interventional). RESULTS: 172 orthopedic surgeons and 160 neurologists fi lled out the questionnaires, which represent about 50% of these specialties in Israel. In the orthopedic questionnaire, when a fi rst opinion had already been given, there was a shift toward a more interventionist treatment (P < 0.05). This was especially prominent when the fi rst opinion was known to the second physician. When the patient intended to seek a second opinion, there was a shift toward a more conservative treatment. No such effect was found among neurologists. CONCLUSIONS: Physicians' judgment may be affected by another physician's opinion (compared to their choices without a fi rst opinion). This bias mainly tends toward a more interventionist treatment. Due to the immense impact of any decision on patient health and resource use, further research should address such biases and develop tools to address them. Regulators and payers view randomized controlled trials (RCT) as the gold standard for establishing the benefi t/risk of new drugs. However, they are increasingly interested in real-world data (RWD) due to their external validity. This survey explored stakeholders' perceptions and emerging trends in the area of RWD. METHODS: We identifi ed relevant literature since 2006 via Google Scholar and manual search, and reviewed it based on several topics: types of RWD, pros and cons of different approaches, and impact of new statistical techniques and technology on availability and quality of RWD. We then conducted 45-60 min in-depth, semistructured discussions with 17 experts from Academia, HTA bodies, health insurance, research organizations, and pharmaceutical industry-from the UK, France, Germany, the The Netherlands, and the United States. Their views about value and future directions of RWD approaches were elicited. RESULTS: Experts unanimously thought that RCTs would remain a mandatory approach for the foreseeable future due to the limitations of RWD, mainly potential for confounding. New study designs (e.g., randomized database studies) and statistical techniques (e.g., high-dimensional propensity scoring) remove confounding only partially and need to gain credibility. There was a strong view that, while registries have been the reference source of observational data, there is an opportunity for (claims) database and electronic medical records to form an effi cient platform for automatic, real-time analysis of naturalistic data. Despite a few good examples, it will, however, require time to resolve technical diffi culty of linking databases and, crucially, the challenges of data ownership and privacy issues. Several experts predict the short-term rise of at-home monitors, "smart pills," and "smart phones" that automatically feed into databases, and the increased use of data from Google Health and Microsoft HealthVault. CONCLUSIONS: RWD may eventually become the new gold standard in drug development, but this will occur only through incremental progress.
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